A multi-site, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence by Winhusen, Theresa M. et al.
Virginia Commonwealth University
VCU Scholars Compass
Social Work Publications School of Social Work
2014
A multi-site, double-blind, placebo-controlled pilot
clinical trial to evaluate the efficacy of buspirone as a
relapse-prevention treatment for cocaine
dependence
Theresa M. Winhusen
University of Cincinnati
Frankie Kropp
University of Cincinnati
Robert Lindblad
EMMES Corporation
See next page for additional authors
Follow this and additional works at: https://scholarscompass.vcu.edu/socialwork_pubs
Part of the Social Work Commons
This Article is brought to you for free and open access by the School of Social Work at VCU Scholars Compass. It has been accepted for inclusion in
Social Work Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
https://scholarscompass.vcu.edu/socialwork_pubs/28
Authors
Theresa M. Winhusen, Frankie Kropp, Robert Lindblad, Antoine Douaihy, Louise Haynes, Candace
Hodgkins, and Karen G. Chartier
This article is available at VCU Scholars Compass: https://scholarscompass.vcu.edu/socialwork_pubs/28
A multi-site, double-blind, placebo-controlled pilot clinical trial
to evaluate the efficacy of buspirone as a relapse-prevention
treatment for cocaine dependence
Theresa M. Winhusen, Ph.D.a, Frankie Kropp, M.S.a, Robert Lindblad, M.D.b, Antoine
Douaihy, M.D.c, Louise Haynes, M.S.W.d, Candace Hodgkins, Ph.D.e, Karen Chartier, Ph.D.f,
Kyle M. Kampman, M.D.g, Gaurav Sharma, Ph.D.b, Daniel F. Lewis, B.A.a, Paul
VanVeldhuisen, Ph.D.b, Jeff Theobald, B.S.a, Jeanine May, Ph.D.b, and Gregory S. Brigham,
Ph.D.a,h
aAddiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University
of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
bThe EMMES Corporation, Rockville, MD, USA
cAddiction Medicine Services, Pittsburgh, PA, USA
dLexington/Richland Alcohol & Drug Abuse Council, Columbia, SC, USA
eGateway Community Services, Jacksonville, FL, USA
fNexus Recovery, Inc., Dallas, TX, USA
gDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA, USA
hMaryhaven, Columbus, Ohio, USA
Abstract
Objective—To evaluate the potential efficacy of buspirone as a relapse-prevention treatment for
cocaine dependence.
Method—A randomized, double-blind, placebo-controlled, 16-week pilot trial conducted at six
clinical sites between August 2012 and June 2013. Adult crack cocaine users meeting DSM-IV-
TR criteria for current cocaine dependence scheduled to be in inpatient/residential substance use
disorder (SUD) treatment for 12–19 days when randomized, and planning to enroll in local
outpatient treatment through the end of the active treatment phase were randomized to buspirone
titrated to 60 mg/day (n=35) or to placebo (n=27). All participants received psychosocial treatment
as usually provided by the SUD treatment programs in which they were enrolled. Outcome
measures included maximum days of continuous cocaine abstinence (primary), proportion of
cocaine use days, and days-to-first-cocaine-use during the outpatient treatment phase (study weeks
4–15) as assessed by self-report and urine drug screens.
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Results—There were no significant treatment effects on maximum continuous days of cocaine
abstinence or days to first cocaine use. In the females (n=23), there was a significant treatment-by-
time interaction effect (X2(1)=6.06, p=.01), reflecting an increase in cocaine use by the buspirone,
relative to placebo, participants early in the outpatient treatment phase. A similar effect was not
detected in the male participants (n=39; X2(1)=0.14, p=.70).
Conclusions—The results suggest that buspirone is unlikely to have a beneficial effect on
preventing relapse to cocaine use and that buspirone for cocaine-dependent women may worsen
their cocaine-use outcomes.
Trial Registration—Clinical Trials.gov http://www.clinicaltrials.gov; Identifier: NCT01641159
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INTRODUCTION
In 2010, over one million people in the U.S. were abusing or dependent on cocaine1 and in
Europe cocaine use has increased significantly in recent years.2 Though psychosocial
interventions for cocaine dependence can help, treatment dropout followed by relapse to
cocaine use is high. Despite extensive work, there still is no FDA-approved treatment for
cocaine dependence.3 Pre-clinical research has found that dopamine D3 receptor antagonists
can reduce the rewarding effects of cocaine and reinstatement of cocaine seeking.4–6 In
addition, imaging research suggests that dopamine D3 receptors may be upregulated in
stimulant abusers.7 Buspirone is an FDA-approved treatment for generalized anxiety
disorder with little abuse potential8 and a well-established safety profile.9 Buspirone has
long been established to be a 5HT1A agonist,8 but in more recent years has been determined
to be a dopamine D310, 11 and D4 antagonist11 as well. Buspirone has been found to
significantly decrease cocaine-cue reinstatement in rats12 and both acute11, 13 and chronic14
buspirone have been found to decrease cocaine self-administration in rhesus monkeys.
Based on the pre-clinical data showing buspirone’s ability to decrease cocaine reinstatement
and self-administration, combined with its favorable safety profile, a clinical trial, “A
Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with
Cocaine Dependence (BRAC)”, was conducted by the National Institute on Drug Abuse
(NIDA) National Drug Abuse Treatment Clinical Trials Network (CTN) to test the efficacy
of buspirone as a cocaine-dependence treatment. Prior research suggests that stimulant-
dependent patients vary substantially in their response to dopaminergic agents15 and, thus,
testing for subgroups for whom buspirone might be differentially effective was planned for
in the trial.16 One subgroup of interest in this regard is gender given evidence that gender
plays a significant role in dopaminergic function and response to dopaminergic agents.17–23
Specific to cocaine, research has found that male monkeys who become dominant have an
increase in dopamine D2/D3 receptors and evidence less vulnerability to the reinforcing
effects of cocaine while female monkeys who become dominant also have an increase in
dopamine D2/D3 receptors but evidence more vulnerability to cocaine’s reinforcing
effects.24
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As described elsewhere,16 BRAC was designed to be a two-stage process in which a pilot
trial would first be completed to obtain information needed to address important operational
aspects critical to the design of the full-scale clinical trial (e.g., medication tolerability,
adherence, missing data rates, eligibility criteria, etc.). The results from the pilot, including
an evaluation of gender effects, are reported in the present paper.
METHODS
Study Design
BRAC was a 16-week, double-blind, placebo-controlled, intent-to-treat (ITT) trial. Dose
titration was completed in an inpatient/residential setting which allowed an evaluation of
buspirone as a relapse-prevention treatment, and based on the potential relapse rate of 65%–
72%,25–27 also of its ability to curtail on-going cocaine use. Eligible participants were
randomized to buspirone or matching placebo and scheduled to receive study medication
and to attend two research visits per week throughout the active treatment phase, which
began with randomization and ended on day 7 of study week 15. A single visit was
scheduled in week 16 to complete retrospective data for week 15. The trial was conducted at
six substance use disorder (SUD) treatment programs between August 2012 and June 2013.
The study was registered on ClinicalTrials.gov (identifier: NCT01641159).
Participants
Recruitment was primarily from patients seeking inpatient/residential treatment at a
participating site; secondary recruitment methods included advertising and direct community
promotions, such as networking with community professionals. Eligible participants were
adults scheduled to be in inpatient/residential SUD treatment for 12–19 days when
randomized, and planning to enroll in local outpatient treatment through the end of the
active treatment phase. Participants were required to meet DSM-IV-TR criteria for current
cocaine-dependence, to have used crack cocaine a minimum of four times in the 28 days
prior to inpatient/residential admission, and to report that their typical pattern of use was at
least once a week. Study eligibility was limited to crack cocaine users in the interest of
increasing sample homogeneity. Exclusion criteria included a medical or psychiatric
condition potentially making participation unsafe, taking psychotropic medication or a
medication with which buspirone could have a potentially dangerous interaction, and
meeting criteria for current opioid dependence; for women, pregnancy, breastfeeding, or
unwillingness to use adequate birth control. All participants were given a thorough
explanation of the study and signed an informed consent form approved by the Institutional
Review Boards of the participating sites.
Procedures
The small sample size for this pilot trial necessitated selecting a single dose of buspirone to
be evaluated; the dose evaluated, 60 mg, is the highest FDA-approved dose for treating
generalized anxiety disorder. Participants were randomized to buspirone (60 mg per day) or
matching placebo in a 1:1 ratio stratified by site and baseline cocaine use frequency (<10
days or ≥ 10 days in the 28 days prior to inpatient/residential admission). Dose escalation
was completed over a 10-day period under observation on an inpatient/residential unit in
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daily divided doses starting with 10 mg on study days 1–3, 20 mg on study days 4–6, 40 mg
on study days 7–9 and 60 mg on day 10. Participants who were unable to reach the 60 mg
dose or needed to be reduced from 60 mg due to tolerability were maintained on 15 mg, 30
mg, or 45 mg, whichever was the highest dose tolerated. All participants received
psychosocial treatment as usually provided by the inpatient/residential and outpatient
programs in which they are enrolled (i.e., treatment as usual (TAU)). For the inpatient/
residential phase, the minimum allowable TAU was at least one therapeutic activity daily
(including milieu therapy) for 12 – 19 days. For the participants’ post-discharge treatment,
the minimum allowable TAU was at least one hour of individual or group therapeutic
activity per week through study week 15.
During the 15-week treatment phase, participants were scheduled to attend two research
visits per week for efficacy and safety assessments. Participants were reimbursed for
transportation, inconvenience, and time; a participant attending all 31 post-randomization
research visits earned $955. To help assure good medication adherence with buspirone’s
required twice daily dosing, all participants could also earn monetary rewards through
contingency management (CM) for opening their medication bottle within six hours of a
prescribed dose time (i.e., three hours before or after the dose was to be taken). The Med-ic
eCAP system (Information Mediary Corporation, Ottawa, Ontario), which is a medication
bottle with a microchip that records the times and dates of bottle opening, was used to track
medication bottle openings. The CM plan involved a relatively quick escalation of
reinforcement earnings as a strategy to promote consistent opening of the medication bottle,
with resets to initial reinforcement values for failing to open the bottle as scheduled. A
participant who was fully adherent throughout the 15-week active treatment phase could
earn a total of $798.50. Reinforcements were provided in the form of retail gift cards
(minimum $5 value), with the provision of cash for reinforcements less than $5. The
buspirone and placebo participants earned an average of $453.10 (SD=187.81) and $427.40
(SD=209.62), respectively.
Measures
The primary outcome was the maximum days of continuous cocaine abstinence during the
outpatient treatment phase (e.g., study weeks 4–15), as assessed by UDS and self-report. A
rapid UDS system that screened for cocaine, methamphetamine, amphetamine, opioids,
benzodiazepines, and marijuana was used to analyze the urine samples (Branan Medical
Corporation, Irvine, California). To avoid falsification, urine samples were collected using
temperature monitoring and the validity of urine samples was checked with a commercially
available adulterant test. Self-report of substance use was assessed using the Timeline
Follow-back (TLFB) method,28 which is a widely employed and well-validated method.
Cocaine abstinence was determined by aggregating TLFB and UDS results into a single
binary daily composite use indicator. More specifically, an algorithm was developed to
combine UDS and TLFB for classifying each day and follows the general principle that a
UDS covers a four day look-back period spanning days −3 to 0, where day 0 is when the
urine is donated. A positive UDS for which the associated TLFB reports are negative results
in “correcting” TLFB days to be cocaine use days. Assumptions are also required for
assigning missing UDS dates in scenarios when a UDS is missing. Details on the rules for
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assigning a day of collection for missing UDS and for combining TLFB and UDS that
accounts for missing UDS results has been published elsewhere.16
Secondary outcomes included proportion of cocaine-use days and days to first cocaine use
as assessed by UDS and TLFB during the outpatient treatment phase. Safety was assessed
through adverse event (AE) reporting and suicide risk assessments. Medication adherence
measures included pill counts, participant self-reported adherence, and Med-ic eCAP data.
Finally, a biological measure of adherence was obtained for participants in the buspirone
arm. Specifically, urine samples were collected weekly during the treatment period and
shipped to the University of California San Francisco School of Pharmacy Drug Studies
Unit, Analytical Division for analysis. The samples from the buspirone group were assayed
for the buspirone metabolite 1-pyrimidinylpiperazine (1-PP) using a liquid chromatography/
mass spectrometry method.
Data Analysis
All analyses were completed on the ITT sample using SAS, Version 9.3 (SAS Institute, Inc.,
Cary, North Carolina). Statistical tests were conducted at a 5% Type I error rate (two-sided)
for all measures. The overall rate of missed visits was only 4.4%. Missing data for the
primary outcome and days-to-first use variables were imputed as being positive for cocaine
use while missing data for the proportion of cocaine use days ignored missing data. The
primary outcome variable (maximum days of continuous cocaine abstinence) was tested for
a treatment effect using a gamma generalized linear regression. Daily composite cocaine use
indicators were tested for treatment and treatment-by-time effects using a logistic
generalized mixed model regression. For graphs of daily composite cocaine use, daily
percentages were pooled into weekly percentages to improve the clarity of presentation.
Days-to-first-cocaine-use was tested for a treatment effect using a Cox Proportional Hazards
regression. The days-to-first-use survival graphs display the by-treatment survival
probability distributions as estimated using Kaplan-Meier calculations on raw data. For each
outcome, the respective regression was performed using all ITT participants, and then
repeated using female ITT participants, and using male ITT participants. All regressions
used baseline proportion of self-reported cocaine use days as a covariate.
RESULTS
Participants and Disposition
As shown in Figure 1, 379 candidates were pre-screened, 100 were consented and screened,
and 62 were randomized to buspirone (n=35) or placebo (n=27). Approximately 94% of
participants completed the 15-week active treatment period, with no group differences on
completion rate or reasons for non-completion. No participant discontinued the study due to
an AE. Demographic and baseline characteristics did not differ significantly between groups
for the sample as a whole or within gender subgroup. The sample was approximately 63%
male and 73% African American, and participants were 46 years of age on average (Table
1).
Winhusen et al. Page 5
J Clin Psychiatry. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Medication Adherence
Medication adherence and tolerability did not differ significantly between treatment groups
for the sample as a whole or within gender subgroup (Table 2). Study participants self-
reported taking an average of 90% of the prescribed pills over the course of the study, and
participants took, on average, 95% of pills dispensed based on pill count. Based on the Med-
ic eCAP data, an average of 85% of the scheduled twice-daily bottle openings occurred
across the study participants. The overall rate of urines positive for 1-PP in the buspirone
group was 81.5% on average across study participants over all study weeks (Table 2).
During the first 7 weeks of the trial, an average of 93.6% of urines were positive for 1-PP in
the buspirone participants overall with rates of 95.5% and 92.8% in the female and male
subgroups, respectively (data not shown). All study participants reached the target dose (60
mg/day) and approximately 89% of participants were maintained at the target dose.
Efficacy Outcomes
All participants (n=62)—The average maximum number of days of continuous cocaine
abstinence was 39.7 (SD=31.4) for the buspirone and 42.1 (SD=31.1) for the placebo
participants, which was not a statistically significant difference (X2(1)=0.05, p=.82). In
contrast, there was a significant treatment-by-time interaction for proportion of cocaine-use
days (X2(1)=6.06, p=.01). A review of the associated graph (Figure 2A) indicates that this
effect reflects a relative increase in use by the buspirone group early in the outpatient
treatment phase (i.e., weeks 5–8). Kaplan-Meier curves for the probability of maintaining
abstinence from cocaine as a function of treatment are provided in Figure 2B; there was no
statistically significant treatment effect on days to first cocaine use (X2(1)=0.15, p=0.70).
Females (n=23)—The average maximum number of days of continuous cocaine
abstinence was 37.7 (SD=32.5) for the buspirone and 52.0 (SD=32.9) for the placebo
participants, which was not a statistically significant difference (X2(1)=1.80, p=.18). In
contrast, there was a significant treatment-by-time interaction for proportion of cocaine-use
days (X2(1)=15.26, p<.0001). A review of the associated graph (Figure 2C) indicates that
this effect reflects a relative increase in cocaine use by the buspirone group early in the
outpatient treatment phase (i.e., weeks 4–10). There was a trend for a significant treatment
effect on days to first cocaine use (X2(1)=3.20, p=.067), reflecting the tendency for quicker
relapse to cocaine use in the buspirone, relative to placebo, participants (Figure 2D).
Males (n=39)—The average maximum number of days of continuous cocaine abstinence
was 40.5 (SD=31.6) for the buspirone and 34.3 (SD=28.1) for the placebo participants,
which was not a statistically significant difference (X2(1)=3.06, p=.08). There was no
significant treatment effect (X2(1)=0.01, p=.91) or treatment-by-time interaction
(X2(1)=0.14, p=.70) for proportion of cocaine-use days (Figure 2E). Finally, there was no
statistically significant treatment effect on days to first cocaine use (X2(1)=1.40, p=.24;
Figure 2F).
Safety outcomes
The occurrence of treatment emergent adverse events (TEAEs) related to study medication
was significantly higher in the buspirone, relative to placebo, group (Table 3). Within
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gender subgroups, the occurrence of TEAEs related to study medication was significantly
higher in the buspirone, relative to placebo, group in the females but not in the males (Table
3). One AE, dizziness, occurred at a rate of 5% or more in the buspirone group, and at a
statistically significantly higher rate than in the placebo group in the sample overall (p=.
0005) and in the females (p=.005); there was a trend for greater dizziness in the buspirone
than the placebo group in the males (p=.057). There was no evidence of an increased risk for
suicidal ideation in the buspirone group. Three participants, all of whom were in the
buspirone arm, experienced a treatment emergent serious adverse event (SAE). The three
events, which were rated as unrelated to the study medication, entailed inpatient hospital
admissions for lower respiratory infection (n=1), chest pain (n=1), and pneumonia (n=1).
DISCUSSION
The present pilot trial was the first to evaluate buspirone as a relapse-prevention treatment
for cocaine dependence. The pilot was successful in demonstrating the feasibility of
conducting a large-scale trial based on enrollment, dose escalation tolerability, and
adherence. The study however, even with small numbers and, counter to prediction, suggests
that buspirone had no beneficial effect on relapse to cocaine use and had a significant
negative effect on proportion of cocaine-use days in female participants. This suggests that
the use of buspirone for cocaine-dependent women may worsen their cocaine-use outcomes,
although, given the small sample of women in the trial (n=23), this finding would need to be
replicated before being given significant consideration clinically. The results for the male
participants revealed no significant buspirone treatment effect which suggests that buspirone
is not an effective cocaine-dependence treatment for males but, again, based on the small
sample of men in the trial (n=39), this finding would also need to be replicated prior to
concluding that buspirone is not effective.
The results from the present pilot trial are inconsistent with pre-clinical studies finding that
buspirone significantly decreases cocaine-cue reinstatement in rats12 and that both
acute11, 13 and chronic14 buspirone decrease cocaine self-administration in rhesus monkeys.
Of import, these pre-clinical studies have been completed only with males and, thus, the
discrepancy between the pre-clinical and present study results may reflect, in part, gender
differences in dopaminergic function and dopaminergic-agent response.17–23 The present
results are consistent with a small (n=35) 12-week double-blind, placebo-controlled trial
evaluating the association between impulsivity, severity of cocaine use, and buspirone
treatment, which found no significant treatment effect of buspirone on cocaine-use
outcomes.29
The present study had several strengths. First, this trial was conducted at 6 sites, which
enhances the generalizability of the results. Another study strength is that it was conducted
with individuals seeking treatment at SUD treatment programs and, thus, the results are
likely generalizable to individuals in treatment for stimulant-dependence disorders.30 Other
strengths include the very high retention and good medication adherence rates. The small
sample size of the present trial is a significant limitation in that small trials do not provide
accurate estimates of treatment effect,31 nor was this study adequately powered to detect
differences in efficacy outcomes since the primary goal of this study was to address
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important operational aspects that would be applied to a second, larger trial. However, the
results from this pilot trial do not provide a strong rationale for conducting a larger follow-
up trial. Evaluation of a single dose of buspirone is another potential limitation of the
present trial. There is evidence that buspirone’s affinity for D3 and D4 receptors is
comparable to its affinity for 5HT1A receptors and, thus, standard clinically-effective doses
would likely effect D3 and D4.32 The dose evaluated in this trial, 60 mg, is the highest FDA-
approved dose for treating generalized anxiety disorder and, thus, would be expected to
occupy D3 and D4 receptors. Still, an evaluation of other doses of buspirone might have
produced different results from those observed in this trial. In conclusion, the results from
the present trial suggest that buspirone is not an effective relapse-prevention treatment for
cocaine dependence and may have a significant negative effect on cocaine-use outcomes in
cocaine-dependent women.
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Clinical Points
• There is currently no FDA-approved medication for the treatment of cocaine-
dependence.
• Buspirone, which is an FDA-approved treatment for generalized anxiety
disorder, may have a significant negative effect on cocaine-use outcomes in
cocaine-dependent women.
• Buspirone does not appear to be an effective relapse prevention treatment for
cocaine dependence.
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Figure 1.
Participant Disposition
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Figure 2.
Proportion of cocaine use days and Kaplan-Meier curves for maintaining cocaine abstinence
as a function of treatment arm for all participants (A, B), females (C, D), and males (E, F).
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